Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma

Cancer

Volumn 116, Issue 17, 2010, Pages 4069-4077

  Chua, Terence C ^a   Chu, Francis ^a   Butler, S Patrick ^a   Quinn, Richard J ^a   Glenn, Derek ^a   Liauw, Winston ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Hepatocellular carcinoma; Iodine 131; Lipiodol; Multifocal

Indexed keywords

IODINATED POPPYSEED OIL; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; CANCER STAGING; CONFIDENCE INTERVAL; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTPATIENT DEPARTMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR VOLUME; VIRUS HEPATITIS; CARCINOMA, HEPATOCELLULAR; DISEASE FREE SURVIVAL; INTRAARTERIAL DRUG ADMINISTRATION; LIVER NEOPLASMS; PALLIATIVE THERAPY;

AGED; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INJECTIONS, INTRA-ARTERIAL; IODINE RADIOISOTOPES; IODIZED OIL; LIVER NEOPLASMS; MALE; PALLIATIVE CARE;

EID: 77956826252     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25283     Document Type: Article

References (21)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
2. Jelic S, On behalf of the EGWG. Hepatocellular carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(suppl 4):iv41-iv45.
3. Lee NW, Wong J, Ong GB. The surgical management of primary carcinoma of the liver. World J Surg. 1982;6:66-75. (Pubitemid 12066483)
4. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995;221:291-298.
5. El-Serag HB, Siegel AB, Davila JA, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158-166; comment 2006;44:8-10.
6. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127(5 suppl 1):S179-S188.
7. Looney WB, Trefil JS, Schaffner JC, Kovacs CJ, Hopkins HA. Solid tumor models for the assessment of different treatment modalities: I. Radiation-induced changes in growth rate characteristics of a solid tumor model. Proc Natl Acad Sci U S A. 1975;72:2662-2666.
8. Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2002;54:150-155.
9. Lau WY, Lai EC. Treatment of unresectable hepatocellular carcinoma with transarterial radioembolization: iodine-131-Lipiodol. ANZ J Surg. 2008;78:331-332.
10. Raoul JL, Boucher E, Roland V, Garin E. 131-iodine Lipiodol therapy in hepatocellular carcinoma. Q J Nucl Med Mol Imaging. 2009;53:348-355.
11. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
12. Kane RC, Farrell AT, Madabushi R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist. 2009;14:95-100.
13. Borbath I, Lhommel R, Bittich L, et al. 131I-Labelled-iodized oil for palliative treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2005;17:905-910.
14. Boucher E, Garin E, Guylligomarc'h A, Olivie D, Boudjema K, Raoul J-L. Intra-arterial injection of iodine-131-labeled Lipiodol for treatment of hepatocellular carcinoma. Radiother Oncol. 2007;82:76-82.
15. Kanhere HA, Leopardi LN, Fischer L, Kitchener MI, Maddern GJ. Treatment of unresectable hepatocellular carcinoma with radiolabelled Lipiodol. ANZ J Surg. 2008;78:371-376; comment 2008;78:331-332.
16. Marelli L, Shusang V, Buscombe JR, et al. Transarterial injection of I-Lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. J Nucl Med. 2009;50:871-877.
17. Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med. 1994;35:1782-1787.
18. Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology. 1997;26:1156-1161.
19. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739.
20. Groupe d'Etude et de Traitement du Carcinome H. A comparison of Lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995;332:1256-1261.
21. Chung-Mau L, Henry N, Wai-Kuen T, et al. Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171.